A

tyr Pharma, a tiny San Diego biotech, has snapped up a pretty broad swath of patents that “cover an entirely new area of biology,” as CEO John Mendlein puts it.

Atyr’s immune-modulating drug candidates are based on cell-signaling molecules that the company has dubbed “physiocrines,” which are thought to have evolved over billions of years to help with an organism’s homeostasis, or state of equilibrium.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Question: do they patent the protein-building enzymes themselves, or they way they produce them, and/or the way they use them?

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.